Medline (NASDAQ:MDLN) Receives $47.83 Consensus Target Price from Brokerages

Shares of Medline (NASDAQ:MDLN) have been assigned an average recommendation of “Moderate Buy” from the thirty-one research firms that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating, twenty-three have issued a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $46.7037.

A number of research firms have weighed in on MDLN. William Blair began coverage on shares of Medline in a report on Monday. They set an “outperform” rating on the stock. Truist Financial started coverage on shares of Medline in a research report on Monday. They set a “buy” rating and a $52.00 target price on the stock. Wells Fargo & Company began coverage on Medline in a report on Monday. They issued an “equal weight” rating and a $42.00 price target on the stock. Stifel Nicolaus began coverage on shares of Medline in a report on Monday. They set a “buy” rating and a $46.00 price objective for the company. Finally, BNP Paribas Exane began coverage on Medline in a research report on Monday. They set a “neutral” rating and a $38.00 target price on the stock.

Medline Price Performance

Shares of MDLN stock opened at $43.41 on Monday. Medline has a twelve month low of $34.89 and a twelve month high of $45.50.

Key Headlines Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Several major brokers initiated bullish coverage or set high price targets (Truist $52, Evercore $50, BTIG $50, Goldman $49, Sanford Bernstein $49, UBS $48, RBC $47, BMO $45, Leerink/Baird strong-buy). Those reports signal upward earnings/market-share expectations and provide concrete upside targets for investors, supporting the rally. Analyst Coverage & Targets (Benzinga)
• Neutral Sentiment: Widespread coverage initiations across big banks (Deutsche Bank, Jefferies, Wells Fargo, JPMorgan, Citigroup, Barclays, Mizuho, TD Cowen, Wolfe Research, Rothschild/Redburn, BNP Paribas Exane) increase the stock’s visibility and institutional research footprint—likely to lift liquidity and investor interest over time but not an immediate fundamental change on its own. Coverage Initiations (AmericanBankingNews)
• Neutral Sentiment: Press coverage highlighting a strong market debut and “aging dividend” thematic interest has helped momentum traders and retail investors take notice; this amplifies the technical lift but is not new company-specific fundamental news. Market Debut Coverage (NAI500)
• Negative Sentiment: Not all firms are uniformly bullish—BNP Paribas and Rothschild/Redb issued “hold” ratings for now. These more cautious views could cap near-term upside if other analysts temper forecasts or if results miss elevated expectations. Hold Ratings (Zacks)

Insider Buying and Selling

In other news, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the completion of the transaction, the insider owned 4,806,160 shares in the company, valued at approximately $136,350,759.20. This represents a 55.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Andrew J. Mills acquired 2,586,206 shares of the company’s stock in a transaction on Thursday, December 18th. The shares were acquired at an average cost of $29.00 per share, for a total transaction of $74,999,974.00. Following the completion of the acquisition, the director owned 2,586,206 shares of the company’s stock, valued at approximately $74,999,974. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.